Regulatory uniQure sets course to US filing for Huntington gene therapy PharmaphorumShares in uniQure have rocketed this morning, as it emerges that the FDA will not require it to run a new trial of Huntington's gene therapy AMT-130.NeuroscienceRead full story pharminent June 17, 2026 (Last updated: June 18, 2026) Pharmaphorum Shares in uniQure have rocketed this morning, as it emerges that the FDA will not require it to run a new trial of Huntington’s gene therapy AMT-130. Neuroscience Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Jazz orchestrates a $4bn cancer alliance with AbCelleraNext: Next Post Related Stories Regulatory FDA, Moderna appear aligned on mRNA flu shot heading into adcomm pharminent June 16, 2026 Regulatory FDA and MHRA forge new regulatory collaboration initiative pharminent June 16, 2026 Regulatory FDA clears MSD’s Keytruda combo plus Welireg for ccRCC treatment pharminent June 15, 2026
